for a healthy life." The study is set to start December 2024 at the nuHx headquarters in West Palm Beach and conclude May 2025 with published study results to follow. nuBioAge and its partner network will continue to pioneer unique studies like...
tissue and the validation of the immunological mechanism of action of the vaccine. The trial is expected to commence in 2025 and is projected to last approximately two to three years. Immunological responses to the vaccine will be made available as...
Vaxxas’ novel HD-MAP as well as through conventional needle and syringe. Initial results from the trial are expected in 2025 and will be provided to BARDA and published by Vaxxas and its clinical collaborators. "Global pandemic threats require the...
The NDA has been granted priority review, with a Prescription Drug User Fee Act (PDUFA) action date of January 29, 2025. "We are grateful to the patients, families, and physicians who participated in the studies that supported this new drug...
in a timely, safe and convenient way.” This year, the CDC recommends everyone ages 6 months and older receive updated 2024-2025 COVID-19 and flu vaccines, with rare exceptions. The CDC says that the concurrent administration of both vaccines is...
CVS Health® announced that the updated 2024-2025 COVID-19 vaccines and flu vaccines are available at CVS Pharmacy® and MinuteClinic® locations nationwide. Walk-ins are being accepted at CVS Pharmacy and the company's digital vaccine scheduler has...
in AI-powered diagnostics,” said Joseph Mossel, CEO at Ibex. “As we progress in the second half of the year and into 2025, these milestones not only solidify our market position but also reflect our ongoing dedication to providing clinicians with...
immune cells implicated in the pathogenesis of MS in patients. We expect to dose the first patient in the first half of 2025." Jonathan Benjamin, M.D., Ph.D., chief medical officer of ImmPACT Bio stated, "The dual-targeting nature of IMPT-514...
local concentration in the oral cavity, aiming to minimize systemic toxicity. The trial is anticipated to conclude by mid-2025, with top-line data expected year-end 2024. Dr. Michael Chancellor, Chief Medical Officer of Lipella added, “We have...
having topline results for both UC and CD in Q4 2024, and detailed results will be presented in a scientific forum in 2025. This adjustment replaces the previously planned interim analysis for the second half of 2024, which will not be conducted....
agreement, Biotest is expected to begin supplying Yimmugo® to Kedrion in Q4 2024, with a market launch planned for Q1 2025. The U.S. IG market is expected to grow by roughly 9% per year in the next eight years, representing an increasing patient...
patients, continues to support the ongoing Phase 1/2 AIPT study (called CRSPA – NCT04195347), with data expected in 2025, and has initiated its Phase 2 study (called KOURAGE – NCT06374797) in AKI with associated AHRF with data expected in 2025....
is on track to be dosed in the treatment phase (Phase 3 trial) in June with enrollment completion expected in early 2025. The company's observational study in children with ISS (111-903) has begun enrolling patients, and the Phase 2 treatment arm...
Leqembi) intravenous (IV) maintenance dosing. A Prescription Drug User Fee Act (PDUFA) action date is set for January 25, 2025. In the US, Leqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment...
We continue to advance RBT-1 through the Phase 3 PROTECT study, with top-line data expected in the third quarter of 2025." Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell...
from around the globe. For more information on the Edison Awards, please visit www.edisonawards.com. Applications for the 2025 awards will open this summer. About HemoSonics: HemoSonics, LLC is a medical device technology company focused on acute...
